With legal and shareholder pressure mounting, Bayer AG on Thursday was preparing to launch an initiative to “regain public trust” after its acquisition last year of Monsanto Co. brought Bayer thousands of lawsuits filed by cancer victims and damning revelations of corporate deception surrounding years of health concerns about Monsanto’s glyphosate-based Roundup herbicides.
The plan calls for seeking a new alternative for glyphosate, the chemical herbicide introduced by Monsanto in 1974. Monsanto pushed the chemical to such pervasive use that glyphosate is considered the most widely used herbicide in history and residues of the weed killer are commonly found now in food, water, and human urine. Despite Monsanto denials of adverse human health and environmental impacts, scientific studies have tied Monsanto’s glyphosate-based herbicide products to a range of disease and illness and have documented weed resistance problems, pollinator declines, soil degradation and water contamination issues, among other concerns.
After three stunning courtroom losses in California, the legal battle over the safety of Monsanto’s top-selling Roundup herbicide is headed for the company’s hometown, where corporate officials can be forced to appear on the witness stand, and legal precedence shows a history of anti-corporate judgments.
Sharlean Gordon, an cancer-stricken woman in her 50s, is the next plaintiff currently set for trial. Gordon v. Monsanto starts Aug. 19 in St. Louis County Circuit Court, located just a few miles from the St. Louis, Missouri-area campus that was the company’s longtime world headquarters until Bayer bought Monsanto last June. The case was filed in July 2017 on behalf of more than 75 plaintiffs and Gordon is the first of that group to go to trial.